AlphaFold represents a fundamental break from centuries of scientific tradition: it solves one of biology's hardest problems using 93 million neural network parameters instead of elegant equations. The breakthrough challenges the assumption that nature is fundamentally simple and that scientific progress requires tidy, unified theories. Instead, it demonstrates that modern science increasingly relies on vast datasets and computational power rather than human-crafted principles.

How Has Scientific Method Changed With AI?

For three centuries, scientists followed a clear playbook: find simple, elegant laws that explain complex phenomena. Isaac Newton captured the motion of planets and cannonballs with just four equations. Einstein unified space and time in a handful of elegant formulas. This approach, guided by a principle called Occam's Razor, assumed that nature itself was fundamentally simple and that the right theory would be beautiful.

Protein folding refused to cooperate with this method. A protein is a chain of amino acids, and the exact sequence determines its three-dimensional shape. That shape, in turn, determines everything about what the protein does in the body. For over 50 years, scientists could not predict protein structure from sequence alone, a problem sometimes called Levinthal's Paradox. The challenge is that protein folding involves interactions between individual atoms, hydrogen bonds, and electrostatic forces all operating at the same scale simultaneously. Unlike planetary motion, you cannot ignore the fine details.

When DeepMind's AlphaFold 2 was unveiled at the CASP14 competition in 2020, it obliterated expectations. The competition's organizers declared the protein folding problem effectively solved. But the solution looked nothing like Newton's elegant laws. AlphaFold 2 is a system of roughly 93 million trainable parameters that predicts three-dimensional atomic coordinates. By traditional standards of scientific virtue, it fails on every count: it is not simple, not elegant, and does not explain why proteins fold the way they do.

"If Newton gave us a cathedral built from four axioms, AlphaFold gave us a cathedral built from 93 million fitted stones, and nobody can quite tell you why each stone sits where it does," explained Eric B. Winsberg, a philosopher of science at the University of South Florida.

Eric B. Winsberg, Philosopher of Science

What Makes AlphaFold's Approach Different From Earlier AI Methods?

The evolution of AlphaFold across three generations reveals a surprising pattern: while the final model is enormously complex, the recipe for building it has become increasingly simple. AlphaFold 1, which debuted in 2018, was a multi-step pipeline combining deep convolutional neural networks with a separate physics-based system called Rosetta software. It was what researchers call a "Rube Goldberg machine" of clever parts, each requiring domain expertise to build and tune.

AlphaFold 2 replaced this with "end-to-end" architecture, eliminating the back-and-forth between statistics and physics. But the architecture itself remained highly specific to protein folding, with each component custom-designed for the geometry of the problem. AlphaFold 3, released in 2024, simplified things even further. Researchers stopped relying on specialized modules and used a diffusion model instead. The bespoke Evoformer was streamlined into a leaner module called the Pairformer. Most remarkably, AlphaFold 3 now handles not just proteins but DNA, RNA, small-molecule drugs, and metal ions, all within a single unified framework.

• Decreasing Domain Expertise: With each generation, scientists use less domain-specific engineering and rely more on general methods that leverage larger datasets and more computation.
• Unified Framework: AlphaFold 3 abandoned specialized components in favor of a single architecture that handles multiple molecular types simultaneously.
• The Bitter Lesson: General methods that scale with data and computation consistently outperform systems built on painstakingly hand-crafted human knowledge, a pattern AI researcher Rich Sutton calls the bitter lesson.

Why Does This Matter for the Future of Science?

The shift from elegant theory to data-driven prediction is reshaping what scientists value in their work. The simplicity that once guided scientific progress has not disappeared; it has moved from the scientific model itself to the method for constructing models. Take a large neural network, feed it a large dataset, and train it to reward correct predictions and punish incorrect ones. This same recipe is now solving protein folding, generating fluent prose, predicting weather systems, and playing superhuman chess.

This transformation is already accelerating pharmaceutical research. By mid-2026, roughly 50 percent of pharma and biotech companies are leveraging artificial intelligence and big data in research and development, up sharply from the late 2010s. Nearly 85 percent of global large pharmaceutical companies now consider AI an "immediate priority." Global healthcare AI funding surpassed 18 billion dollars in 2025, accounting for roughly 46 percent of all health-sector investment.

Early adopters report tangible returns on investment. Drug-target identification times have been cut in half, from roughly 18 months to 9 months. AI-assisted operations improve efficiencies across the board. For example, Syneos Health cut trial site activation time by roughly 10 percent using AI systems. Venture financing of AI-driven drug discovery and biotech rose to roughly 11 billion dollars in 2025, up from roughly 8.9 billion dollars in 2024.

However, adoption remains uneven. While enthusiasm is high, most organizations are still piloting or in early phases. Recent surveys find only 13 to 30 percent of companies have fully implemented AI programs, with the majority still testing or planning. Barriers include data silos, cost, talent gaps, and regulatory concerns, meaning the industry is still in a "slow-and-steady" uptake phase.

The philosophical implications are profound. For centuries, scientists assumed that simplicity was a guide to truth because nature itself was fundamentally simple. AlphaFold suggests a different possibility: there may be regions of reality in which traditional scientific theorizing is helpful, but there is no reason to insist that this applies to reality in its entirety. The future of science may depend less on finding elegant equations and more on harnessing computational power to navigate complexity that humans cannot easily understand.